Cianergoline (), also known as 355/1057 or as 2-cyano-3-(6-methylergolin-8β-yl)propionamide (2-CMEBP), is a dopamine receptor agonist described as an antihypertensive agent of the ergoline family which was never marketed. It has atypical properties as a dopamine receptor agonist compared to other ergolines, for instance having less central activity and showing predominant cardiovascular effects. In addition to its dopamine receptor agonism, cianergoline may interact with α-adrenergic receptors, which may or may not also be involved in its antihypertensive effects. The drug was first described in the scientific literature by 1983.Riva, F., & Sardi, A. (1984). Cianergoline. Drugs of the Future, 9, 13. https://scholar.google.com/scholar?cluster=14938482905837820153 It was studied for treatment of essential hypertension.
See also Substituted ergoline
References